Nasdaq:NPCE
NeuroPace Inc
NeuroPace Inc. is a clinical-stage biotech firm developing its proprietary NeuroCybernetic Control System to treat drug-resistant pediatric epilepsy without medication.
Key Metrics
Investment Thesis
Bull Case
Investors might consider NeuroPace as a high-risk, high-reward opportunity given its potential to capture a large addressable market in pediatric drug-resistant epilepsy with a first-in-class product offering. The narrowing net loss trajectory combined with growing revenue suggests the company is successfully transitioning from pure R&D toward sustainable commercial operations.
Bear Case
The investment case is weakened by the company's reliance on external capital to fund operations, evidenced by a cash burn rate that exceeds its current liquid assets and available marketable securities. Significant debt levels and a substantial retained earnings deficit of $531 million create financial fragility that could prevent the company from weathering regulatory delays or slowing sales growth.
About NeuroPace Inc
NeuroPace Inc. develops and manufactures the NeuroCybernetic Control System (NCS), an implantable device designed to treat pediatric patients with drug-resistant epilepsy. The company operates primarily in the specialized medical technology sector, serving hospitals and healthcare providers globally by offering a non-pharmacological alternative for managing severe seizure disorders.
Analysis
Management Discussion
Despite a continued net loss of $27.1 million in the latest period, NeuroPace demonstrated improving operational efficiency as losses narrowed from $47.1 million in 2022 and $33.0 million in 2023 while revenue grew to nearly $80 million. However, cash flow from operations remains negative at $-17.9 million, indicating that the company is still burning significant capital to fund its research, development, and commercialization efforts.
Industry Overview
The medical device industry for epilepsy treatment is highly competitive, dominated by pharmaceutical companies selling antiepileptic drugs and established neurostimulation firms offering vagus nerve stimulation therapies. NeuroPace competes in this space by providing a distinct implantable solution that offers a non-drug alternative, though it faces stiff competition from both pharmacological treatments and other neuromodulation technologies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $45.5M | $65.4M | $79.9M |
| Cost of Revenue | $13.0M | $17.3M | $20.8M |
| Gross Profit | $32.5M | $48.1M | $59.1M |
| Operating Expenses | $73.3M | $75.3M | $80.8M |
| Operating Income | $-40.8M | $-27.2M | $-21.7M |
| R&D | $21.9M | $20.8M | $23.7M |
| G&A | $51.3M | $54.5M | $57.1M |
| Stock-Based Comp | $8.3M | $9.6M | $10.3M |
| Depreciation | $267.0K | $172.0K | $207.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $7.5M | $8.5M | — |
| Interest Income | $1.6M | $3.0M | $3.0M |
| Pre-Tax Income | $-40.8M | $-27.2M | $-21.7M |
| Income Tax | $6.3M | $5.8M | $5.5M |
| Continuing Ops | $-47.1M | $-33.0M | $-27.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-47.1M | $-33.0M | $-27.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-47.1M | $-33.0M | $-27.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $97.7M | $92.7M | $81.3M |
| Cash & Equivalents | $6.6M | $18.1M | $13.4M |
| Marketable Securities | $70.8M | $48.4M | $39.3M |
| Accounts Receivable | $7.5M | $12.3M | $12.9M |
| Inventory | $9.7M | $11.2M | $13.4M |
| Prepaid Expenses | $3.1M | $2.7M | $2.4M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $16.4M | $14.9M | $13.3M |
| PP&E (Net) | $1.1M | $1.0M | $1.1M |
| Operating Leases | $14.8M | $13.4M | $11.8M |
| Other LT Assets | $490.0K | $524.0K | $413.0K |
| Total Assets | $114.1M | $107.7M | $94.6M |
| Current Liabilities | $11.0M | $16.2M | $15.2M |
| Accounts Payable | $2.1M | $2.3M | $3.0M |
| Current Leases | $1.4M | $1.6M | $1.9M |
| Deferred Revenue | — | $1.1M | $555.0K |
| Other Current Liab | $0 | $0 | $0 |
| Long-Term Liabilities | $68.4M | $70.8M | $71.5M |
| Long-Term Debt | $52.9M | $57.0M | $59.5M |
| LT Operating Leases | $15.4M | $13.8M | $12.0M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $79.3M | $87.0M | $86.6M |
| Shareholders' Equity | $34.8M | $20.7M | $8.0M |
| Paid-In Capital | $506.7M | $524.4M | $538.9M |
| Retained Earnings | $-470.9M | $-503.8M | $-531.0M |
| AOCI | $-1.1M | $0 | — |
| Total L&E | $114.1M | $107.7M | $94.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-47.1M | $-33.0M | $-27.1M |
| Non-Cash Adjustments | $8.4M | $3.4M | $9.5M |
| Working Capital Changes | $1.8M | $9.8M | $-311.0K |
| Cash from Operations | $-36.9M | $-19.7M | $-17.9M |
| Capital Expenditures | $603.0K | $173.0K | $306.0K |
| Cash from Investing | $23.8M | $23.0M | $9.0M |
| Cash from Financing | $490.0K | $8.1M | $4.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-12.6M | $11.5M | $-4.6M |
| Beginning Cash | $19.3M | $6.7M | $18.2M |
| Ending Cash | $6.7M | $18.2M | $13.6M |
Frequently Asked Questions
How does NeuroPace Inc make money?
The company's revenue is derived principally from the sale and licensing of its NeuroCybernetic Control System (NCS) implantable device, along with associated procedural kits, remote monitoring software, and maintenance services for existing implants. Given the clinical-stage nature and high R&D spend relative to revenue, operations are currently dominated by research and development activities alongside limited commercial sales.
What are the main risks for NPCE?
As a clinical-stage biotechnology company, NeuroPace faces significant commercialization risk as it seeks to scale sales after receiving FDA approval for its primary device. The company carries substantial debt obligations totaling approximately $59.5 million with limited cash reserves of $13.4 million, creating potential liquidity concerns if revenue growth slows or financing is delayed.
What is NPCE's competitive advantage?
NeuroPace holds a unique market position as one of the few companies offering an implantable neurocybernetic device that detects and terminates seizures before they occur, bypassing the need for daily medication. The company possesses proprietary technology with strong intellectual property protection in the form of patents covering its detection algorithms and control system architecture.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.